Respiratory Syncytial Virus (RSV) hospitalises thousands of children each year, yet effective treatments remain unavailable. This research investigates a critical protein–protein interaction that enables RSV infection. By identifying and disrupting key molecular binding sites using AI, the work aims to support the development of targeted antiviral therapies for severe RSV.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.